Therapeutic method for pancreatic cancer
The present invention relates to methods and medicarnents useful for treating locally advanced pancreatic cancer (LAPC). Improved therapeutic methods and regimens comprising anti-connective tissue growth factor (CTGF) agents, including anti-CTGF antibodies, are provided. Included are induction therapies for converting unreseetable LAPC into borderline or resectable status.
1. A method of treating locally advanced pancreatic cancer (LAPC) in a subject with unresectable locally advanced pancreatic cancer, the method comprising:
administering an anti-connective tissue growth factor (CTGF) antibody that is identical to the CLN-1 antibody produced by ATCC Accession No. PTA-6006 at a dose of at least about 35 mg/kg, gemcitabine at a dose of about 1000 mg/m 2 , and nab-paclitaxel at a dose of about 125 mg/m 2 ;
restaging the subject by laparascopic examination; and
if the LAPC is downstaged to resectable or borderline resectable status, then resecting the LAPC.
2. The method of claim 1 , wherein the antibody is administered on days 1 and 15 and the gemcitabine and nab-paclitaxel are administered on days 1, 8 and 15 of a 28 day treatment cycle.
3. The method of claim 2 having up to six treatment cycles before restaging.
4. The method of claim 3 , wherein a 35 mg/kg loading dose of the antibody is administered on day 8 of the first treatment cycle.
5. The method of claim 1 , wherein the LAPC is an adenocarcinoma.
6. The method of claim 5 , wherein the adenocarcinoma is ductal adenocarcinoma.